Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer, Carcinoma
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
PRINCIPAL INVESTIGATORS Rakesh Patel, MD- Radiation Oncologist Peter Beitsch, MD- Breast Surgeon REGISTRY DESIGN Multicenter, non-randomized, post market registry of intracavitary accelerated partial breast irradiation in…
- Conditions
- Breast Cancer, Carcinoma, Lumpectomy, Ductal Carcinoma in Situ
- Trial name
- EXIBT (NCT00742222)
- Testing
- Electronic Brachytherapy, Intracavitary accelerated partial breast irradiation
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- Xoft, Inc.
Breast Cancer Metastatic
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Exploring the efficacy and safety of zoledronic acid combined with neoadjuvant chemotherapy (EC-T) in neoadjuvant treatment for early-stage or locally advanced triple-negative breast cancer, the trial protocol of zoledronic acid…
- Trial name
- NCT06876636
- Testing
- Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Xijing Hospital
Breast Cancer, Breast Cancer Female
Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer
This study involves a course of radiation to the tumor that is delivered BEFORE surgery. The type of radiation is called stereotactic ablative body radiation therapy (SABR).
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Adenocarcinoma
- Trial name
- NCT03137693
- Testing
- Standard of Care Schedule Variation: SABR, Breast-conserving Surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Early Breast Cancer, Premenopausal Breast Cancer
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Rationale: Around 70 to 80% of breast cancers are so-called "hormone-dependent" (HR+)/HER2-. For more than 50 years, studies have shown that chemotherapy and optimised hormonal treatments (hormone therapy), including a drug…
- Conditions
- Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
- Trial name
- OPTIMA-YOUNG (NCT07106632)
- Testing
- test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone, In the control arm, the treatment will be as standard of care : chemo-endocrine therapy
- Where
- 105 sites in Belgium, France and 5 more
- Volunteers
- 3,380 people
- Sponsor
- UNICANCER
HR+/HER2-breast Cancer
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
This is a randomized, controlled, open, phase III trial of adjuvant intensive therapy for early breast cancer with HR+/ HER2-SNF4 based on SNF molecular typing.
- Trial name
- NCT05889871
- Testing
- Standard endocrine therapy plus Apatinib
- Volunteers
- 916 people
- Sponsor
- Fudan University
Decision Making ,Shared, De-escalation
Enhancing Shared Decision-Making in Metastatic Breast Cancer (Qualitative Study)
Develop a Metastatic Breast Cancer (MBC)-specific electronic Treatment Plans (TP). Phase 1: Aim 1a: Patient interviews along with navigator, nurse, and physician focus group discussions will be used to identify factors that…
- Trial name
- NCT03248258
- Testing
- Qualitative Interview or Focus group discussions
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Early-stage Breast Cancer
Cardioprotective Effect of Acute Exercise in Breast Cancer Patients
Cardiotoxicity is one of the most significant adverse effects in breast cancer patients treated with anthracyclines (a type of chemotherapy), so we propose to determine whether acute training (i.e., 24h before each chemotherapy…
- Trial name
- CardioProtEx (NCT05467111)
- Testing
- Acute Exercise
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Technical University of Madrid
Breast Cancer
CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer
The investigators designed a phase III clinical trial involving hormone receptor-positive and HER2-positive stage I breast cancer patients.
- Trial name
- Cinderella (NCT07213206)
- Testing
- CDK 4/6 inhibitor combined therapy (omit chemo), standard of care
- Volunteers
- 1,500 people
- Sponsor
- Fudan University
Breast Cancer, Estrogen Receptor-Positive, HER2 Low Breast Cancer
A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
This is a prospective, open-label, multicenter, single-arm clinical study designed to compare the efficacy and safety of neoadjuvant treatment with T-DXd in combination with an immune checkpoint inhibitor in patients with primary…
- Trial name
- NCT06733233
- Testing
- T-DXd combined with immune checkpoint inhibitor
- Volunteers
- 23 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Breast Cancer, HER2-positive Breast Cancer
Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP
This is a prospective, multi-center, single-arm, phase 2 exploratory study to evaluate the efficacy and safety of adding 4 cycles of Trastuzumab Rezetecan (T-DXh), an anti-HER2 antibody-drug conjugate, as continued neoadjuvant…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Trial name
- NCT07589699
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
Patients with estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) breast cancer do not achieve good responses with pre-operative chemotherapy.
- Trial name
- NCT05069038
- Testing
- Palbociclib 125mg
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Nebraska
Breast Cancer, Health Behavior
Effect of Planned Education on Health Beliefs and Fatalism in Women at High Risk of Breast Cancer
Purpose: This project aims to examine the effects of planned education on health beliefs and fatalism in women at high risk of breast cancer.
- Conditions
- Breast Cancer, Health Behavior, Breast Self-Examination
- Trial name
- NCT06690320
- Testing
- IMPLEMENTATION OF A PLANNED EDUCATION PROGRAM ON HEALTH BELIEF MODEL AND FATUALIST TENDENCIES IN WOMEN AT HIGH RISK OF BREAST CANCER
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Ege University
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
Identification of Early Markers of Response and Resistance to Trastuzumab
The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab. It is a prognostic factor study recruiting all consecutive cases of HER-2 positive breast cancer eligible for a…
- Trial name
- HERBIN (NCT01834950)
- Testing
- Blood test
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer (Early Breast Cancer)
ADC Based Therapy Accroding to HER2 Heterogeneous
This study adopts a single-center, open-label, single-arm interventional design. It will enroll 88 patients with histologically confirmed HER2-positive early breast cancer who are suitable for surgery and neoadjuvant therapy, and…
- Trial name
- HER2level (NCT07844018)
- Testing
- HER2 target therapy
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking University People's Hospital
HER2-negative Breast Cancer
AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer
This is a prospective, randomized and open-label phase II study, evaluating the efficacy and safety of AT vs TP regimen as neoadjuvant treatment for early HER2-negative breast cancer.
- Trial name
- NCT04499118
- Testing
- AT regimen, TP regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sichuan Provincial People's Hospital
Triple Negative Breast Cancer (TNBC)
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Breast cancer is one of the most common malignant tumors in women, accounting for the first cancer-related death cause in women. In recent years, the incidence has gradually increased, and the trend is younger.
- Trial name
- NCT07187674
- Testing
- Iparomlimab and tuvonralimab combined with olaparib and paclitaxel
- Volunteers
- 20 people
- Sponsor
- Harbin Medical University
Early Breast Cancer, Ductal Breast Carcinoma In Situ
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
- Trial name
- HFCBB (NCT06984250)
- Testing
- Hypofractionated Radiation Therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 315 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This non-randomized, multicenter, open-label study will assess the safety and efficacy of subcutaneously administered trastuzumab in participants with early and locally advanced HER2-positive breast cancer in two sequential…
- Trial name
- SCHEARLY (NCT01940497)
- Testing
- Doxorubicin, Docetaxel, Paclitaxel
- Where
- 54 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
The purpose of this research study is to compare the efficacy and safety of EG12014 with Herceptin as neoadjuvant treatment for 12 weeks, followed by surgery and subsequent EG12014 or Herceptin adjuvant treatment for up to 12…
- Trial name
- NCT03433313
- Testing
- EG12014, Herceptin
- Where
- 91 sites in United States, Belarus and 9 more
- Volunteers
- 807 people
- Sponsor
- EirGenix, Inc.
Breast Cancer
Investigation of the Prognostic Value of Patterns of Genomic Alterations or Protein Expression in Patients With Operated Early Breast Cancer
This study retrospectively analyze tumor samples and clinical data from Greek women with operable breast cancer of intermediate or high-risk of relapse who participated in HeCOG adjuvant studies.
- Trial name
- NCT07630558
- Where
- Greece
- Volunteers
- 1,891 people
- Sponsor
- Hellenic Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.